D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease

Thrombosis and Haemostasis

Volumn 110, Issue 2, 2013, Pages 233-243

  Kleinegris, Marie Claire F ^a   ten Cate, Hugo ^a   ten Cate Hoek, Arina J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Arterial thrombotic events; D dimer; Fibrin degradation products; Intermittent claudication; Peripheral arterial disease

Indexed keywords

BIOCHEMICAL MARKER; D DIMER;

ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; FOLLOW UP; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMATIC REVIEW;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; THROMBOSIS;

EID: 84880848986     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-01-0032     Document Type: Article

References (50)

1. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997; 2: 221-226.
2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-67.
3. Smith FB, Rumley A, Lee AJ, et al. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100: 758-763.
4. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 1990; 82: 1925-1931.
5. Bainton D, Sweetnam P, Baker I, et al. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. Br Heart J 1994; 72: 128-132.
6. Banerjee AK, Pearson J, Gilliland EL, et al. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992; 68: 261-263.
7. Smith FB, Lowe GD, Fowkes FG, et al. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 1993; 102: 155-162.
8. Koksch M, Zeiger F, Wittig K, et al. Haemostatic derangement in advanced peripheral occlusive arterial disease. Int Angiol 1999; 18: 256-262.
9. Vidula H, Tian L, Liu K, et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med 2008; 148: 85-93.
10. Lee AJ, Fowkes GR, Lowe GD, et al. Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1995; 15: 1094-1097.
11. Lee AJ, Fowkes FG, Lowe GD, et al. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 1995; 74: 828-832.
12. Lowe GD, Rumley A. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost 1999; 82: 667-672.
13. Smith EB, Keen GA, Grant A, et al. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-275.
14. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
15. Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 2517-2522.
16. Ridker PM, Hennekens CH, Cerskus A, et al. Plasma concentration of crosslinked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-2240.
17. Tataru MC, Heinrich J, Junker R, et al. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 1999; 20: 1493-1502.
18. Stott DJ, Spilg E, Campbell AM, et al. Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinolysis 2001; 12: 651-657.
19. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 493-498.
20. Zakai NA, Katz R, Jenny NS, et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost 2007; 5: 1128-1135.
21. Wannamethee SG, Whincup PH, Shaper AG, et al. Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J Thromb Haemost 2009; 7: 1605-1611.
22. Lowe GD, Sweetnam PM, Yarnell JW, et al. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004; 24: 1957-1962.
23. Lowe GD, Yarnell JW, Rumley A, et al. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001; 21: 603-610.
24. Folsom AR, Aleksic N, Park E, et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21: 611-617.
25. Gottesman RF, Cummiskey C, Chambless L, et al. Hemostatic factors and subclinical brain infarction in a community-based sample: the ARIC study. Cerebrovasc Dis 2009; 28: 589-594.
26. Tzoulaki I, Murray GD, Lee AJ, et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J 2007; 28: 354-362.
27. Yarnell J, McCrum E, Rumley A, et al. Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study. Eur Heart J 2005; 26: 332-342; discussion 17-18.
28. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103: 2323-2327.
29. Smith FB, Lee AJ, Fowkes FG, et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-3325.
30. Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007; 115: 2119-2127.
31. Cortellaro M, Cofrancesco E, Boschetti C, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group. Arterioscler Thromb 1993; 13: 1412-1417.
32. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. J Am Med Assoc 2007; 297: 1197-1206.
33. Cacoub PP, Abola MT, Baumgartner I, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis 2009; 204: e86-92.
34. Rehring TF, Sandhoff BG, Stolcpart RS, et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005; 41: 816-822.
35. Kmet LM, Lee R, Cook LS. Standard quality assessment Criteria for Evaluating primary Research Papers from a variety of fields: Alberta Heritage Foundation for Medical Research. 2004.
36. NHS Centres for Review and Dissemination. Undertaking systematic reviewers of research of effectiveness: CRD's guidance for those carrying out or commissioning reviews. 2nd ed. York: University of York: 2001.
37. Cortellaro M, Cofrancesco E, Boschetti C, et al. Association of increased fibrin turnover and defective fibrinolytic capacity with leg atherosclerosis. The PLAT Group. Thromb Haemost 1994; 72: 292-296.
38. Vidula H, Tian L, Liu K, et al. Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels. Am J Cardiol 2010; 105: 1348-1352.
39. Bosevski M, Kostoska S, Tosev S, et al. Prognostic importance of haemostatic parameters in polyarterial disease. Prilozi 2005; 26: 81-92.
40. Fowkes FG, Lowe GD, Housley E, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84-86.
41. Komarov A, Panchenko E, Dobrovolsky A, et al. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J 2002; 23: 1309-1316.
42. Boneu B, Leger P, Arnaud C. Haemostatic system activation and prediction of vascular events in patients presenting with stable peripheral arterial disease of moderate severity. Royat Study Group. Blood Coagul Fibrinolysis 1998; 9: 129-135.
43. Bosevski M, Kostoska S, Tosev S, et al. Usefulness of D-Dimers and fibrinogen plasma determination in patients with polyvascular disease. Angiol Sosud Khir 2006; 12: 9-15.
44. Criqui MH, Ho LA, Denenberg JO, et al. Biomarkers in peripheral arterial disease patients and near- and longer-term mortality. J Vasc Surg 2010; 52: 85-90.
45. Musicant SE, Taylor LM, Jr,Peters D, et al. Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease. J Vasc Surg 2006; 43: 772-780.
46. Lowe GD. Fibrin D-dimer and cardiovascular risk. Semin Vasc Med 2005; 5: 387-398.
47. Willeit P, Thompson A, Aspelund T, et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS One 2013; 8: e55175.
48. de Maat MP, Meijer P, Nieuwenhuizen W, et al. Performance of semiquantitative and quantitative D-dimer assays in the ECAT external quality assessment program. Semin Thromb Hemost 2000; 26: 625-630.
49. Boeer K, Siegmund R, Schmidt D, et al. Comparison of six D-dimer assays for the detection of clinically suspected deep venous thrombosis of the lower extremities. Blood Coagul Fibrinolysis 2009; 20: 141-145.
50. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-227.